“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Amylin Pharmaceuticals


A–Z list of Amylin Pharmaceuticals’ products

Byetta (exenatide)
Indication: Type 2 diabetes management (adjunct to oral antidiabetic agents)
Dose: 5–10 micrograms subcutaneous injection, twice daily before meals

Bydureon (exenatide extended-release)
Indication: Type 2 diabetes management
Dose: 2 mg subcutaneous injection, once weekly

Symlin (pramlintide acetate)
Indication: Adjunct therapy to insulin in type 1 and type 2 diabetes not achieving glycemic control
Dose: 15–60 micrograms subcutaneous injection before meals, titrated by response

Metreleptin (recombinant leptin, pipeline)
Indication: Metabolic disorders associated with lipodystrophy
Status: Development for diabetes and hypertriglyceridemia; explored for weight and metabolic control

AC165198 (pipeline peptide hybrid)
Indication: Investigational therapy for diabetes
Status: Early-stage development, dosing not publicly established



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)